Successful Exit: BayBG and Founding Family Sell Blood Bank Specialist Lmb Technologie GmbH
Lmb Technologie Enters New Growth Phase with French Group Macopharma
Munich, April 16, 2025. BayBG and the Jentsch entrepreneurial family have successfully sold their shares in the Lmb Group to the French Macopharma GMPi group as part of a succession solution. With this transaction, Macopharma, a leading expert in blood processing solutions, strengthens its market position across Europe, the Americas and the Middle East. The purchase price remains confidential.
Based in Schwaig (Germany), Lmb Technologie GmbH has been developing and distributing innovative medical devices for blood donation, separation and logistics worldwide for more than 40 years. Its main products — blood separators — are exported to 80 countries, with consumables for blood and stem cell banks complementing the product portfolio.
BayBG recognized the potential of Lmb Technologie early on and invested in 2013 to accelerate growth and prepare for long-term succession.“Even back then, we were impressed by the management’s expertise, innovative strength and the overall quality of the medical technology company,” says Christian Fiederling, Head of Growth at BayBG.
“Demand for blood separation devices has increased significantly,” adds Investment Manager Elke Jung. “That is why we provided a follow-on investment in 2020, enabling further technological innovations.”
“Blood is highly valuable and global demand has grown strongly in recent years. With BayBG at our side, we were able to significantly drive our international expansion,” says Klaus Jentsch, founder and managing director of Lmb Technologie. “We are grateful for the reliable commitment and trusting partnership, and are delighted to have found a renowned industry successor in Macopharma to continue Lmb’s growth.”
BayBG Bayerische Beteiligungsgesellschaft
BayBG, headquartered in Munich, is one of the leading equity investors for medium-sized companies (the “Mittelstand”), with an invested volume of €382 million. Venture capital and minority equity investments, including mezzanine financing, enable companies to implement innovation and growth projects, manage corporate succession, drive transformation or optimize their capital structure. BayBG operates as an evergreen investor and is not subject to exit pressure.
Press Contact:
Franziska Roederstein
Phone: 089 122280-174